Well, everyone wants once weekly or longer dosing schedule for Hemophilia A. I suppose it is not that easy. BIIB's rFVIII can be dosed once every week for some, twice every week for others - I haven't looked at their detailed data yet. Thus twice weekly is not that bad. This might be reason BAX-NKTR still have research in place for potentially longer acting Advate than BAX855. BIIB's long acting rFIX can be dosed once every week or every two weeks for Hemophilia B.
I don't have good sense on how pain efficacy endpoint would do.
Market Data 
Markets 
AI
